SCHEMBL1774576

SCHEMBL1774576

Cc1cc(NCC(O)(CC(C)(C)c2cc(F)ccc2O)C(F)(F)F)c2cnn(-c3cccc(C(=O)N(C)CC(N)=O)c3)c2c1

nearest known ligand 0.59

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 20/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1774593 0.92 NR3C1 (0.71) NR3C1
SCHEMBL1774678 0.88 NR3C1 (0.61) NR3C1
SCHEMBL1775338 0.85 NR3C1 (0.61) NR3C1
SCHEMBL1776757 0.85 NR3C1 (0.60) NR3C1
SCHEMBL304018 0.84 NR3C1 (0.56) NR3C1
SCHEMBL1775897 0.82 NR3C1 (0.86) NR3C1
SCHEMBL1775081 0.82 NR3C1 (0.86) NR3C1
SCHEMBL3183031 0.82 NR3C1 (0.78) NR3C1
SCHEMBL9609142 0.82 NR3C1 (0.62) NR3C1
SCHEMBL1774457 0.82 NR3C1 (0.71) NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2013185-B1 NOVEL COMPOUNDS GLAXO GROUP LTD (GB) 2012-05-30 EP claimed
US-20090111866-A1 Novel Compounds GLAXO WELLCOME HOUSE (GB) 2009-04-30 US claimed
EP-2013185-B1 NOVEL COMPOUNDS GLAXO GROUP LTD (GB) 2012-05-30 EP disclosed
US-8178573-B2 Compounds GLAXO GROUP LIMITED (GB) 2012-05-15 US disclosed
US-8178573-B2 Compounds GLAXO GROUP LIMITED (GB) 2012-05-15 US disclosed
US-8178573-B2 Compounds GLAXO GROUP LIMITED (GB) 2012-05-15 US disclosed
US-7943651-B2 Compounds GLAXO GROUP LIMITED (GB) 2011-05-17 US disclosed
US-7943651-B2 Compounds GLAXO GROUP LIMITED (GB) 2011-05-17 US disclosed
US-7943651-B2 Compounds GLAXO GROUP LIMITED (GB) 2011-05-17 US disclosed
US-20090111866-A1 Novel Compounds GLAXO WELLCOME HOUSE (GB) 2009-04-30 US disclosed
US-20090111866-A1 Novel Compounds GLAXO WELLCOME HOUSE (GB) 2009-04-30 US disclosed
US-20090111866-A1 Novel Compounds GLAXO WELLCOME HOUSE (GB) 2009-04-30 US disclosed
US-20070265326-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2007-11-15 US disclosed
US-20070265326-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2007-11-15 US disclosed
US-20070265326-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2007-11-15 US disclosed
WO-2007122165-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265326-A1 NOVEL COMPOUNDS CCL11, MRGPRX2, LTB4R2 NR3C1 190/4885
US-20090111866-A1 Novel Compounds CCL11, MRGPRX2, LTB4R2 NR3C1 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.